Breezula Phase III 12-Month Data Released by Cosmo Pharma
    Research/Science 4/15/2026

    At a glance
    In this research update post, the primary subjects mentioned are
    💧 Clascoterone (topical) 5% 12 months
    the tone is 😀 positive with statistically significant continued hair growth results.

    Other terms

    Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
    View this post in the Community →

    Similar Community Posts Join

    5 / 268 results

      community What’s your views on clascoterone 5% topical solution by cosmo

      in Research/Science  24 upvotes 6 months ago
      Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

      community Clascoterone 12 months phase 3 result out

      in Treatment  45 upvotes 1 month ago
      Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

      community Most promising cures for baldness as of May 2026

      in Treatment  56 upvotes 3 weeks ago
      PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

      community Clascoterone - what we have right now

      in Research/Science  23 upvotes 3 months ago
      Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

    Related Research

    6 / 104 results